Literature DB >> 30170032

Probiotics reduce risk-taking behavior in the Elevated Plus Maze in the Flinders Sensitive Line rat model of depression.

Sandra Tillmann1, Gregers Wegener2.   

Abstract

Several studies have reported beneficial effects of probiotics on behavior and stress in humans and animals. The multi-strain probiotic product Ecologic® Barrier has shown antidepressant-like effects in rats when given in combination with high-fat diet. To circumvent the need for high-fat diet for future clinical use, the present study aimed to potentiate the behavioral effects of Ecologic® Barrier by developing a customized product that includes four additional bacterial species known to be associated with depression. Flinders Sensitive Line (FSL) rats, an animal model of depression, were randomized to receive vehicle, Ecologic® Barrier, or the customized product Ecologic® Barrier + 4. The control strain, Flinders Resistant Line rats, received vehicle to ascertain the depressive-like phenotype of FSL rats. Behavior was tested in the Elevated Plus Maze, Y-Maze, Novel Object Recognition Test, Open Field, and Forced Swim Test; HPA-axis reactivity was assessed by the Dexamethasone Suppression Test. Our results indicate that both probiotic products reduced open arm exploration in the Elevated Plus Maze, suggesting a reduction in risk-taking behavior. There were no intervention effects on cognition, locomotion, or depressive-like behavior. Moreover, all intervention groups had similar plasma corticosterone concentrations following the Dexamethasone Suppression Test. There was no difference between the two probiotic products, suggesting that the addition of four bacterial strains to Ecologic® Barrier did not potentiate its effect. Future studies should further investigate the effects of probiotics on risk-taking behavior and gain more mechanistic insights by studying individual strains and their cumulative contributions to the overall effect of a multi-strain product.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depression; Gut-brain axis; Probiotics; Risk-taking behavior; Stress

Mesh:

Substances:

Year:  2018        PMID: 30170032     DOI: 10.1016/j.bbr.2018.08.025

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  7 in total

1.  The Gut Microbiome as a Component of the Gut-Brain Axis in Cognitive Health.

Authors:  Wen Gao; Kelley L Baumgartel; Sheila A Alexander
Journal:  Biol Res Nurs       Date:  2020-07-17       Impact factor: 2.522

Review 2.  Selecting an Appropriate Animal Model of Depression.

Authors:  Yuanzhen Hao; Huixiang Ge; Mengyun Sun; Yun Gao
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

Review 3.  Animal Models for Functional Gastrointestinal Disorders.

Authors:  Alison Accarie; Tim Vanuytsel
Journal:  Front Psychiatry       Date:  2020-11-11       Impact factor: 4.157

Review 4.  Interplay of Good Bacteria and Central Nervous System: Cognitive Aspects and Mechanistic Considerations.

Authors:  Mahmoud Salami
Journal:  Front Neurosci       Date:  2021-02-11       Impact factor: 4.677

5.  Faecal microbiota transplantation from patients with depression or healthy individuals into rats modulates mood-related behaviour.

Authors:  Julie Kristine Knudsen; Thomas Yssing Michaelsen; Caspar Bundgaard-Nielsen; René Ernst Nielsen; Simon Hjerrild; Peter Leutscher; Gregers Wegener; Suzette Sørensen
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.379

6.  The effects of probiotics on risk and time preferences.

Authors:  Aline M Dantas; Alexander T Sack; Elisabeth Bruggen; Peiran Jiao; Teresa Schuhmann
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

7.  Under or Absent Reporting of Light Stimuli in Testing of Anxiety-Like Behaviors in Rodents: The Need for Standardization.

Authors:  Lorenz S Neuwirth; Michael T Verrengia; Zachary I Harikinish-Murrary; Jessica E Orens; Oscar E Lopez
Journal:  Front Mol Neurosci       Date:  2022-08-17       Impact factor: 6.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.